pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·1h ago·1 min read
save

Novo’s race to catch Lilly; Q3 earnings recap; and more

Nov 7, 2026·read at Endpoints ↗

Welcome back to Endpoints Weekly. Democrats won control of Congress in a wave election on Tuesday. What does that mean for biopharma?

Endpoints News’ Max Bayer and Drew Armstrong discussed the results with policy expert ...

source

Reporting by Endpoints.

read at Endpoints ↗
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 11h agoChurch quits role at AI startup Radical, claims ‘sleazy’ behavior stole credit from partnerEndpoints
  • 19h ago#SITC26: Immunocore reports early data for brenetafusp plus Kimmtrak in uveal melanomaEndpoints
  • 19h agoJ&J’s Rybrevant nets FDA approval in head and neck cancerEndpoints
  • 19h agoSatellos' new Duchenne study endpoint; Amgen's Repatha cuts heart attack riskEndpoints
  • 21h agoSarepta quits enrolling for confirmatory Phase 3 trial of ElevidysEndpoints